Validea Detailed Fundamental Analysis

According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) receives a 62% rating based on their John Neff-inspired Low PE Investor model, which favors firms with persistent earnings growth trading at a discount. While TMO passes tests for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, it fails the P/E ratio and Total Return/PE tests, indicating mixed results based on Neff's value-oriented strategy.

Analysis

Thermo Fisher Scientific Inc. (TMO) received a 62% rating from Validea's Low PE Investor model, which is based on John Neff's strategy favoring firms with persistent earnings growth trading at a discount. This score is below the 80% threshold typically indicating strategy interest, reflecting a nuanced assessment. TMO successfully passed crucial fundamental tests, including those for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, highlighting strong operational performance and a positive outlook for earnings. However, the company failed the P/E ratio and Total Return/PE tests, two key valuation metrics for the Neff strategy, indicating that despite its growth characteristics, TMO does not currently trade at the discount relative to its earnings growth and dividend yield that this specific value-oriented model seeks.

Key Decisions for Investors

• Investors should acknowledge TMO's robust fundamental strengths, such as consistent earnings per share growth, positive future EPS projections, solid sales growth, and healthy free cash flow generation.
• Value-oriented investors, particularly those following strategies similar to John Neff's, should note that TMO currently fails key valuation criteria like P/E ratio and Total Return/PE, suggesting it may not meet strict value investing requirements at its current price.
• Given the mixed signals from the Validea Neff model (62% score), investors should carefully weigh TMO's strong growth attributes against its current valuation to determine if it aligns with their specific investment mandates, recognizing it doesn't fully meet the discount criteria of this particular strategy.